Correlation Between Curis and YS Biopharma
Can any of the company-specific risk be diversified away by investing in both Curis and YS Biopharma at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Curis and YS Biopharma into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Curis Inc and YS Biopharma Co,, you can compare the effects of market volatilities on Curis and YS Biopharma and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Curis with a short position of YS Biopharma. Check out your portfolio center. Please also check ongoing floating volatility patterns of Curis and YS Biopharma.
Diversification Opportunities for Curis and YS Biopharma
0.0 | Correlation Coefficient |
Pay attention - limited upside
The 3 months correlation between Curis and YS Biopharma is 0.0. Overlapping area represents the amount of risk that can be diversified away by holding Curis Inc and YS Biopharma Co, in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on YS Biopharma Co, and Curis is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Curis Inc are associated (or correlated) with YS Biopharma. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of YS Biopharma Co, has no effect on the direction of Curis i.e., Curis and YS Biopharma go up and down completely randomly.
Pair Corralation between Curis and YS Biopharma
If you would invest 48.00 in YS Biopharma Co, on September 3, 2024 and sell it today you would earn a total of 0.00 from holding YS Biopharma Co, or generate 0.0% return on investment over 90 days.
Time Period | 3 Months [change] |
Direction | Flat |
Strength | Insignificant |
Accuracy | 1.56% |
Values | Daily Returns |
Curis Inc vs. YS Biopharma Co,
Performance |
Timeline |
Curis Inc |
YS Biopharma Co, |
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Curis and YS Biopharma Volatility Contrast
Predicted Return Density |
Returns |
Pair Trading with Curis and YS Biopharma
The main advantage of trading using opposite Curis and YS Biopharma positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Curis position performs unexpectedly, YS Biopharma can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in YS Biopharma will offset losses from the drop in YS Biopharma's long position.Curis vs. Aileron Therapeutics | Curis vs. Artelo Biosciences | Curis vs. Histogen | Curis vs. X4 Pharmaceuticals |
YS Biopharma vs. Revelation Biosciences | YS Biopharma vs. Cardio Diagnostics Holdings | YS Biopharma vs. Biodexa Pharmaceticals | YS Biopharma vs. ZyVersa Therapeutics |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Odds Of Bankruptcy module to get analysis of equity chance of financial distress in the next 2 years.
Other Complementary Tools
Stocks Directory Find actively traded stocks across global markets | |
Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities |